Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track IQV with free AI briefings, catalyst countdowns, and dilution alerts.

IQV · IQVIA HOLDINGS INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.1B Cash on Hand

CF+ Cash Runway

Follow IQV by email Get an email when IQV pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IQV, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Dec 2026 · N/A · Active Trial · Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Rou
Registry primary completion date, not a results date
Dec 2026 · Phase 3 · Active Trial · Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Registry primary completion date, not a results date
Jan 2027 · N/A · Recruiting · Pacritinib Effectiveness in Real-world Settings
Registry primary completion date, not a results date
Jan 2027 · Phase 1/2 · Recruiting · Ixovex-1 Single Agent and Combination Therapy
Registry primary completion date, not a results date
Jan 2027 · N/A · Active Trial · Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal
Registry primary completion date, not a results date
Feb 2027 · N/A · Upcoming Trial · I-OPERA: A European Study Testing a New Way to Do Health Research.
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
2.27% glucose peritoneal dialysis dwell	End Stage Renal Disease	N/A · NCT05874804	Completed
Recombinant human alpha-galactosidase A	Fabry Disease	Phase 3 · NCT05843916	Completed
Oregovomab	Carcinoma, Ovarian Epithelial	Phase 3 · NCT04498117	Active not recruiting
Olorofim	Invasive Aspergillosis	Phase 3 · NCT05101187	Active not recruiting
Nomegestrol Acetate	Contraception	Phase 3 · NCT05264506	Terminated
Esomeprazole Magnesium	Erosive Esophagitis	Phase 3 · NCT05267613	Active not recruiting
Medi-546	Systemic Lupus Erythematosus	Phase 3 · NCT04877691	Active not recruiting
GSK3511294 (Depemokimab)	Asthma	Phase 3 · NCT04718389	Completed
Liposomal Amphotericin B	Invasive Aspergillosis	Phase 3 · NCT05101187	Active not recruiting
J147 Emulsion for Injection	Acute Ischemic Stroke	Phase 2 · NCT07430917	Recruiting
Bedaquiline	Drug Susceptible Pulmonary Tuberculosis	Phase 2 · NCT07525427	Recruiting
OG-6219	Endometriosis	Phase 2 · NCT05560646	Completed
NOC-110	Refractory or Unexplained Chronic Cough	Phase 2 · NCT06504446	Active not recruiting
Efgartigimod	Primary Sjögren's Syndrome	Phase 2 · NCT06203457	Completed
Anti-CD137 Agonistic Monoclonal Antibody	Locally Advanced Solid Tumor	Phase 1 · NCT03881488	Completed
Talabostat Mesylate	Cancer of Pancreas	Early Phase 1 · NCT04123574	Withdrawn

Also used in these trials (approved or third-party drugs, not IQV's own candidates): Pegcetacoplan, Acellular Tissue Engineered Vessel, Agalsidase Beta, Paclitaxel, Nirsevimab, Mepolizumab, Benralizumab, Carboplatin, Bevacizumab, Olaparib, Durvalumab (MEDI4736), Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IQV holds $2.1B in cash and short-term investments (as of Mar 31, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IQV files for a raise →

Get the full IQV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IQV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z